Gentherm Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy THRM?
Source: seekingalpha
- Organizational Realignment: Gentherm initiated an organizational realignment in Q1 to reduce management layers, aiming for approximately $10 million in annual OpEx savings, thereby enhancing the company's competitive edge amid market uncertainties.
- Financial Performance: The company reported a record $394 million in product revenue for Q1, with adjusted EBITDA of $49.3 million, representing 12.5% of sales, reflecting strong automotive demand, particularly in China.
- Cost Pressures: Management anticipates approximately $20 million in incremental costs due to geopolitical factors in 2026, and while they plan to mitigate these through operational initiatives, they may still exert pressure on margins in Q2 and Q3.
- Long-term Outlook: Gentherm maintains its full-year revenue guidance between $1.5 billion and $1.6 billion, emphasizing that the merger with Modine Performance Technologies is expected to pave the way for $3.5 billion in revenue and over $0.5 billion in earnings, showcasing confidence in long-term growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THRM
Wall Street analysts forecast THRM stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 29.610
Low
42.00
Averages
43.33
High
44.00
Current: 29.610
Low
42.00
Averages
43.33
High
44.00
About THRM
Gentherm Incorporated is a provider of thermal management and pneumatic comfort technologies. The Company operates in two segments: Automotive and Medical. The Automotive reporting segment comprises global automotive businesses, including the design, development, manufacturing and sales of its automotive climate and comfort solutions (including Climate Control Seats, Climate Control Interiors, Lumbar and Massage Comfort Solutions and Climate and Comfort Electronics), Valve Systems and other automotive products. The Medical reporting segment comprises the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Organizational Realignment: Gentherm initiated an organizational realignment in Q1 to reduce management layers, aiming for approximately $10 million in annual OpEx savings, thereby enhancing the company's competitive edge amid market uncertainties.
- Financial Performance: The company reported a record $394 million in product revenue for Q1, with adjusted EBITDA of $49.3 million, representing 12.5% of sales, reflecting strong automotive demand, particularly in China.
- Cost Pressures: Management anticipates approximately $20 million in incremental costs due to geopolitical factors in 2026, and while they plan to mitigate these through operational initiatives, they may still exert pressure on margins in Q2 and Q3.
- Long-term Outlook: Gentherm maintains its full-year revenue guidance between $1.5 billion and $1.6 billion, emphasizing that the merger with Modine Performance Technologies is expected to pave the way for $3.5 billion in revenue and over $0.5 billion in earnings, showcasing confidence in long-term growth.
See More
- Earnings Beat: Gentherm reported a Q1 Non-GAAP EPS of $0.84, surpassing expectations by $0.33, indicating a significant improvement in profitability and enhanced competitive positioning in the market.
- Revenue Growth: The company achieved revenue of $393.71 million in Q1, an 11.3% year-over-year increase, exceeding market expectations by $31.48 million, demonstrating strong performance in product sales and market demand.
- Cash Flow Improvement: Although cash flow from operations was negative at $(5.0) million, this represents an improvement from $(13.3) million in the prior year, highlighting progress in cash management and operational efficiency.
- Stable Future Guidance: Gentherm's guidance for full-year 2026 remains unchanged, projecting product revenues between $1.5 billion and $1.6 billion and adjusted EBITDA of $175 million to $195 million, reflecting confidence in future growth and a stable business foundation.
See More
- Leadership Change: Modine has announced the promotion of Art Laszlo to President of the newly created Data Centers segment, responsible for driving growth and profitability, indicating a strategic shift in the company's focus towards the data center market.
- Market Opportunity: The establishment of the new Data Centers segment reflects Modine's recognition of the increasing demand for cooling solutions from global data center operators, which is expected to further solidify its market leadership.
- Business Structure Adjustment: The Data Centers segment was previously part of the Climate Solutions segment, and with Laszlo's appointment, Modine will report the performance of these two segments in the first quarter of fiscal 2027, demonstrating the company's emphasis on business segmentation.
- Leadership Experience: Since joining Modine in 2022, Laszlo has progressively advanced to senior leadership roles, and his extensive experience at IDEX and other renowned companies will provide strategic guidance to the new segment.
See More
- Strategic Partnership Announced: Gentherm has partnered with KNB Communications, which will serve as the official PR agency for Gentherm's medical division, leveraging its expertise to support the launch of the ThermAffyx™ Patient Safety System aimed at enhancing patient safety during surgeries.
- Innovative Product Introduction: The ThermAffyx™ Patient Safety System is the first medical device designed to integrate patient warming and securement, addressing dual challenges faced during surgeries, which is expected to significantly improve patient experience and safety in surgical settings.
- FDA Application Progress: Gentherm submitted a 510(k) Class II premarket notification to the FDA for the ThermAffyx™ earlier this year, with clearance anticipated in May, paving the way for market entry and enhancing competitive positioning.
- Significant Market Potential: Gentherm recorded approximately $1.5 billion in annual sales in 2024 and secured $2.4 billion in new automotive business awards, indicating strong growth potential and strategic importance in expanding its footprint in the medical device market, particularly in innovations related to patient safety.
See More










